Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Share News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.55
Bid: 1.50
Ask: 1.60
Change: -0.025 (-1.59%)
Spread: 0.10 (6.667%)
Open: 1.575
High: 1.575
Low: 1.55
Prev. Close: 1.575
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Comptoir opens restaurant; Intercede wins contract

Thu, 07th Dec 2023 15:31

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Comptoir Group PLC - Owner and operator of a chain of Lebanese restaurants - Opens new restaurant at the Southbank Centre, London. The restaurant will be located opposite the entrance of the Royal Festival Hall, neighbouring Las Iguanas, Cote Brasserie and Honest Burgers restaurants. Says that with over 5,400 events a year, the Southbank Centre site has a footfall of 19 million a year. Expects to open restaurant around Easter next year. Chief Executive Nick Ayerst says: "Following the successful recent opening in Ealing, we are pleased to announce the continued strategic growth in an area of London we have long desired to be in. The location on the South Bank captures an immensely high footfall of both workers, visitors and tourists who we know will be hungry for our well-loved authentic Middle Eastern food and culture."

----------

Intercede Group PLC - Lutterworth, England-based cybersecurity software - Wins a professional services order to help deploy MyID Credential Management Solution to "large US Federal Agency." Says it is the same customer which it won a contract with on Tuesday. Says additional order, worth USD800,000, underpins the company's upgraded financial 2024 and 2025 forecasts. "Once again, I am pleased to announce a further order that supports our upgraded forecasts for FY24 and FY25. This is a testament of the hard work my colleagues have done and indeed continue to do so," says CEO Klaas van der Leest. On Tuesday, Intercede said it signed a "major" new contract with the unnamed large US federal agency, with purchase orders received of perpetual licences worth around USD6.6 million. Due to the order, the company expects its financial year 2024 results to be "significantly ahead of market expectations," which it says are a revenue of GBP13.7 million and adjusted earnings before interest, tax, depreciation and amortisation of GBP1.8 million.

----------

Datalex PLC - Dublin-based software company, which specialises in digital retail technology for the airline market - Announces the go live of its Datalex Merchandiser product with easyJet PLC, a Luton Airport-based low-cost airline. Says easyJet is set to begin its migration to Datalex Direct and Datalex Dynamic in 2024 to drive next generation retailing and an improved booking experience. Chief Revenue Officer Bryan Porter says: "We are proud to be partnering with easyJet to drive forward the airline's digital retail strategy, supporting high value revenue growth and enhancing the exceptional customer experience for easyJet's customers. The recent go live is a major milestone in our journey, and we look forward to continuing to provide the airline with superior and innovative digital retailing capabilities that will enable them to deliver new, revenue generating and differentiated customer experiences."

----------

Wynnstay Properties PLC - Powys, Wales-based agricultural and specialist merchanting firm - Exchanges contracts for the acquisition from three members of the Gunne family of Units 1-4, 18a Wildmere Road, Banbury, and Unit 14, The IO Centre, Whittle Way, Stevenage, for GBP2.5 million in total. The Banbury property is freehold and comprises two industrial buildings, separately let to established national and regional trade counter businesses, with service yards and an access road. The total rent passing is GBP103,425 per year. The Stevenage Property is held on a 999-year lease at a nominal rent and comprises a mid-terrace industrial unit. The rent passing on the single occupational sub-lease to an established national trade counter business is GBP57,550 per annum. The acquisition in expected to complete at the beginning of 2024. Chris Betts, Managing Director of Wynnstay, says: "The acquisition of these highly accessible and well-let properties broadens the geographic spread of Wynnstay's portfolio and enhances our focus on the growth potential of the light industrial/trade counter warehouse sector."

----------

Develop North PLC - investor in residential and commercial property sector advised by Newcastle, England-based Tier One Capital Ltd - Extends share buyback programme. Says it will repurchase up to a further GBP500,000. The programme will end December 31. The purchased shares will be held in treasury.

----------

Eqtec PLC - Thermochemical conversion technology company - Signs an equipment supply agreement for engineering services and equipment supply for a plant in Wilseyville, California, US. The plant is being developed to cleanly convert approximately 25,000 tonnes per year of wood waste into synthesis gas to fuel a gas engine coupled to alternators for production of about 3.0 MWe electricity. The Agreement is with Blue Mountain Electric Company LLC, a project company set up and operated by Phoenix Biomass Energy Inc. Expects to commence basic engineering work in early 2024 and to invoice about USD330,000 for this work, which the company expects to complete in the first half of 2024.

----------

Videndum PLC - London-based manufacturer of hardware and software for the content creation market, including broadcasters and film studios - Raises GBP125 million through placing and open offer. Raises GBP75 million through placing of 28.1 million shares and GBP50 million through open offer of 18.7 million shares. CEO Stephen Bird says: "We are pleased with the very strong response to the capital raising and I would like to thank both our shareholders and new investors for their support. We now have a robust capital base which will enable Videndum to focus its resources on strategic execution and long-term value creation for shareholders through our market-leading, premium brands which are focused on the content creation market."

----------

Shield Therapeutics PLC - Commercial-stage pharmaceutical company focusing on its iron deficiency product Accrufer - Updates shareholders on third quarter US commercial highlights. Total prescriptions reach over 27,750, up 76% from the second quarter. Notes US third quarter net revenue of USD4.1 million. CEO Greg Madison comments: "Shield continues to make excellent progress on the US commercial launch of Accrufer. As we approach the one-year anniversary of the announcement of the Viatris agreement, I am pleased to report that the collaboration continues to deliver excellent results, based on the stand-out performance of the combined commercial team, which has produced consistent and strong sequential prescription growth and key performance indicators, which are trending towards previous guidance."

----------

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
17 Apr 2019 18:11

DIRECTOR DEALINGS: Shield Therapeutics Chair Buys GBP40,000 In Shares

LONDON (Alliance News) - Shield Therapeutics PLC said Wednesday Chair James Karis bought 50,000 shares in the company.Karis acquired 46,000 shares at GBP0.815 on Monday, then acquired a at

Read more
3 Apr 2019 10:10

Shield Therapeutics narrows losses as it advances Feraccru to market

(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced a decent improvement in revenue in its preliminary results on Wednesday, to £11.9m from £0.6m.

Read more
3 Apr 2019 09:56

Shield Therapeutics Cuts Loss In 2018; Licence Payment Lifts Revenue

LONDON (Alliance News) - Drug maker Shield Therapeutics PLC said Wednesday its 2018 loss narrowed significantly as revenue surged on a licence payment boost amid a year of "transition" a

Read more
14 Mar 2019 15:52

Shield Therapeutics Secures Positive Decision On Feraccru's Patent

LONDON (Alliance News) - Shield Therapeutics PLC on Thursday said its Feraccru patent met the requirements of the European Patent Convention, which will continue to provide protection to Feraccru

Read more
4 Mar 2019 11:26

Shield Therapeutics upbeat on latest Feraccru trial results

(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced positive results from the AEGIS-H2H clinical trial on Monday, which compared 'Feraccru' (ferric maltol) - a novel oral iron replacement therapy - to 'Ferinject' (ferric carboxymaltose - FCM), the market-leading intravenously delivered iron replacement therapy.

Read more
29 Jan 2019 11:21

Shield Therapeutics Gets Positive Results From Feraccru Study

LONDON (Alliance News) - Shield Therapeutics PLC on Tuesday reported positive results from a long-term study of its lead treatment for iron deficiency, Ferracru.Shares in the company were a

Read more
29 Jan 2019 10:02

Shield Therapeutics upbeat on results of latest Feraccru study

(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced positive results from the open-label extension phase of the AEGIS-CKD pivotal study of 'Feraccru' on Tuesday.

Read more
24 Jan 2019 14:16

Shield Therapeutics Expects 2018 Revenue Growth On Licence Payments

LONDON (Alliance News) - Shield Therapeutics PLC on Thursday said it expects its revenue to surge in 2018 on the back of licence payments for its Feraccru capsules.The pharmaceutical has in

Read more
24 Jan 2019 10:02

Shield Therapeutics revenues surge following commercialisation deal

(Sharecast News) - Shield Therapeutics saw revenues rocket in the second half of its trading year following a commercialisation agreement with European pharmaceutical specialist Norgine.

Read more
22 Jan 2019 13:35

Shield Therapeutics Appoints Director James Karis As Chair

LONDON (Alliance News) - Shield Therapeutics PLC said Tuesday that it has promoted board member James Karis to be non-executive chair with immediate effect.Karis has served on Shield's

Read more
22 Jan 2019 09:56

Shield Therapeutics promotes Karis to chairman

(Sharecast News) - Commercial stage pharmaceutical outfit Shield Therapeutics elevated James Karis to the role of non-executive chairman on Tuesday.

Read more
13 Dec 2018 11:57

FDA gives target date for Shield's Feraccru application

(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced on Thursday that the US Food and Drug Administration (FDA) has confirmed that the target date for completion of the New Drug Application (NDA) review of 'Feraccru', under the terms of the Prescription Drug User Fee Act, would be 27 July 2019.

Read more
5 Dec 2018 13:07

Shield Therapeutics' Feraccru treatment launched in UK

(Sharecast News) - Shield Therapeutics' treatment for iron deficiency in adults, Feraccru, was launched in the UK on Wednesday by specialist pharmaceutical company Norgine.

Read more
5 Dec 2018 11:57

Shield Therapeutics Partner Norgine Launches Feraccru In UK

LONDON (Alliance News) - Shield Therapeutics PLC said Wednesday that Norgine BV has launched the company's treatment for iron deficiency, Ferracru, in the UK.In September 2018, Shield,

Read more
24 Sep 2018 14:30

DIRECTOR DEALINGS: Shield Therapeutics Boss Sterritt Buys More Stock

LONDON (Alliance News) - Shield Therapeutics PLC on Monday said Chief Executive Carl Sterritt bought more shares in the company in a deal on Friday last week.Sterritt pruchased 88,235 at 34

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.